Fig. 1: Pathologic and radiologic responses to neoadjuvant ICB.

a Waterfall plots showing the percentage pathologic regression and the percentage radiographic change from baseline in the sum of the target lesion after neoadjuvant administration of 2 cycles of pembrolizumab (n = 10). The first dotted line indicates the cutoff for radiological partial response (PR) according to RECIST 1.1. The second dotted line depicts the threshold for major pathological response (MPR) corresponding to 90% regression. The orange bar colours reflect the pathologic response (dark orange: MPR; light orange: pathological Partial Response (pPR)). The pink bar colours represent the radiologic response (dark pink: partial response (PR); light pink: stable disease (SD)). Pathological features are annotated for each patient and include histological subtype, tumour grade at baseline and in the resection specimen, (pathologic) FIGO stage after treatment, expression of MisMatch Repair (MMR) proteins, and the aetiology of MMR deficiency (MMRd). The numbers above the bars represent the study ID of each patient. *: no pathologic response; **: no pathologic response and radiologic response not measurable and/or not determined due to Covid restrictions. b Swimmer plot depicting per patient the timeline of follow-up, type of surgery, lymph nodes debulking at time of surgery, type of adjuvant therapy, and recurrence / mortality (n = 10). c Representative MRI images of the uterus pre- versus post-treatment with 2 cycles of neoadjuvant pembrolizumab from PAM-004. Similar experiments conducted for 8 patients d Representative H&E images of pre- versus post-treatment biopsy tissue from PAM-004. The pretreatment biopsy shows a grade 3 endometrioid adenocarcinoma. The post-treatment biopsy shows the fibrotic tumour bed with immune-cell infiltration. Similar experiments conducted for all 10 patients. Source data are provided as a source data file. Abbreviations: ICB immune checkpoint blockade, MRI magnetic resonance imaging, MPR major pathological response, pPR partial pathological response, PR partial response, SD stable disease.